Jeffrey P. Hartung
No más puestos en curso
Historial de carrera de Jeffrey P. Hartung
Antiguos cargos conocidos de Jeffrey P. Hartung.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Director de Operaciones | 01/06/2004 | - |
Formación de Jeffrey P. Hartung.
| University of California San Diego | Doctorate Degree |
| San Diego State University | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
Operativa
| Chief Operating Officer | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffrey P. Hartung
- Experiencia
